* Participants will begin this research study within 14 days of starting Bevacizumab, either as part of standard treatment or as part of another clinical trial.
* Participants will have an ultrasound test done at baseline, and after completion of their first and second cycles of therapy.
* Vital signs and blood tests will be performed a the start of the study, and after completion of the first and second cycles of therapy.
